Loading...
Market
What will be Bavarian Nordic's mpox vaccine market share in Europe by mid-2025?
2
Resolution / Starting Odds
Less than 30% • 25%
30% to 50% • 25%
50% to 70% • 25%
More than 70% • 25%
Market research reports and sales data
Story
Bavarian Nordic Seeks EU Approval for Adolescent Mpox Vaccine
Aug 16, 2024, 07:30 AM
Danish biotech company Bavarian Nordic has submitted data to the European Union's drug regulator seeking approval to extend the use of its mpox vaccine to adolescents. Bavarian Nordic is currently the only company with a vaccine approved for mpox in both the United States and Europe. The company aims to expand the vaccine's usage to a younger demographic, highlighting its ongoing efforts to enhance public health measures against mpox.
View original story
Similar markets
Less than 1 million • 25%
1 to 3 million • 25%
3 to 5 million • 25%
More than 5 million • 25%
Less than 25% • 25%
25-50% • 25%
50-75% • 25%
More than 75% • 25%
Approved by Q3 2024 • 25%
Approved by Q4 2024 • 25%
Approved by Q1 2025 • 25%
Not approved by Q1 2025 • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
UK Government • 25%
Gavi • 25%
WHO • 25%
Other • 25%
Yes • 50%
No • 50%
Nigeria • 25%
Kenya • 25%
South Africa • 25%
Other • 25%
0-10% • 25%
11-20% • 25%
21-30% • 25%
31% or more • 25%
Less than 20% • 25%
20-40% • 25%
41-60% • 25%
More than 60% • 25%
Yes • 50%
No • 50%
Increases by more than 10% • 25%
Increases by 5-10% • 25%
Increases by less than 5% • 25%
Decreases or remains the same • 25%